Imatinib is an effective drug for treating the majority of CML patients, which is mostly attributed to the blockade of the known growth-promoting properties of BCR-ABL1, such as activation of the downstream MAPK, AKT, and STAT pathways. This evidence concerns the gene SOAT1 and chronic myelogenous leukemia, BCR-ABL1 positive.